Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Longitudinal Diffusion-Weighted Whole-Body MRI Demonstrates Dynamic Changes in Muscle Integrity in Motor Neuron Disease.

Pierry IA, Alix J, Rao DG, Hoggard N, Bigley J, McDermott CJ, Wilkinson ID, Shaw PJ, Jenkins TM.

J Neuromuscul Dis. 2018;5(1):107. doi: 10.3233/JND-179002. No abstract available.

PMID:
29278900
2.

Aggressive surgical management of adenocarcinoma of the rete testis.

Maganty A, Fombona A, Bandari J, Lyon TD, Kulich S, Gingrich JR, Bigley JD, Tarin TV.

Urol Case Rep. 2017 Nov 13;16:72-74. doi: 10.1016/j.eucr.2017.10.001. eCollection 2018 Jan.

3.

Imaging muscle as a potential biomarker of denervation in motor neuron disease.

Jenkins TM, Alix JJP, David C, Pearson E, Rao DG, Hoggard N, O'Brien E, Baster K, Bradburn M, Bigley J, McDermott CJ, Wilkinson ID, Shaw PJ.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):248-255. doi: 10.1136/jnnp-2017-316744. Epub 2017 Oct 31.

4.

Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

Wojno KJ, Costa FJ, Cornell RJ, Small JD, Pasin E, Van Criekinge W, Bigley JW, Van Neste L.

Am Health Drug Benefits. 2014 May;7(3):129-34.

5.

Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI.

J Urol. 2014 Oct;192(4):1081-7. doi: 10.1016/j.juro.2014.04.013. Epub 2014 Apr 18.

6.

FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis-associated colorectal neoplasia.

Papadia C, Louwagie J, Del Rio P, Grooteclaes M, Coruzzi A, Montana C, Novelli M, Bordi C, de' Angelis GL, Bassett P, Bigley J, Warren B, Atkin W, Forbes A.

Inflamm Bowel Dis. 2014 Feb;20(2):271-7. doi: 10.1097/01.MIB.0000435443.07237.ed.

PMID:
24280874
7.

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.

Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, O'Donnell M, Clark J, Van Criekinge W, Bigley J, Harrison DJ.

J Urol. 2013 Mar;189(3):1110-6. doi: 10.1016/j.juro.2012.08.219. Epub 2012 Oct 8.

PMID:
22999998
8.

A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection.

Van Neste L, Bigley J, Toll A, Otto G, Clark J, Delrée P, Van Criekinge W, Epstein JI.

BMC Urol. 2012 Jun 6;12:16. doi: 10.1186/1471-2490-12-16.

9.

The epigenetic promise for prostate cancer diagnosis.

Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W.

Prostate. 2012 Aug 1;72(11):1248-61. doi: 10.1002/pros.22459. Epub 2011 Dec 7. Review.

PMID:
22161815
10.

Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.

Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, Klein EA, Jones JS, Wang S, McAskill T, Mehrotra J, Raghavan B, Partin AW.

BJU Int. 2012 Jul;110(1):56-62. doi: 10.1111/j.1464-410X.2011.10718.x. Epub 2011 Nov 11.

11.

The Anatomy of the Medial Lemniscus within the Brainstem Demonstrated at 3 Tesla with High Resolution Fat Suppressed T1-Weighted Images and Diffusion Tensor Imaging.

Romanowski CA, Hutton M, Rowe J, Yianni J, Warren D, Bigley J, Wilkinson ID.

Neuroradiol J. 2011 May 15;24(2):171-6. Epub 2011 May 11.

PMID:
24059604
12.

Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies.

Troyer DA, Lucia MS, de Bruïne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2717-22. doi: 10.1158/1055-9965.EPI-09-0068. Epub 2009 Sep 15.

13.

Neurolinguistic programming used to reduce the need for anaesthesia in claustrophobic patients undergoing MRI.

Bigley J, Griffiths PD, Prydderch A, Romanowski CA, Miles L, Lidiard H, Hoggard N.

Br J Radiol. 2010 Feb;83(986):113-7. doi: 10.1259/bjr/14421796. Epub 2009 Jun 8.

14.

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE 2nd, Bierau K, Bigley J, Bigner DD, Friedman HS.

Mol Cancer Ther. 2006 Oct;5(10):2531-9.

15.
16.

Anesthetic induction with ketamine inhibits platelet activation before, during, and after cardiopulmonary bypass in baboons.

Undar A, Eichstaedt HC, Clubb FJ Jr, Lu M, Bigley JE, Deady BA, Porter A, Vaughn WK, Fung M.

Artif Organs. 2004 Oct;28(10):959-62.

PMID:
15385005
17.

Metabolically controlled reperfusion in acute myocardial infarction: should the polarizing solution be given subselectively?

Angelini P, Haas PC, Bucciarelli Ducci C, Adams S, Ober J, Bigley J, Clubb FJ, Frazier OH.

J Invasive Cardiol. 2003 Sep;15(9):491-6.

PMID:
12947208
18.

Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass.

Undar A, Eichstaedt HC, Clubb FJ Jr, Fung M, Lu M, Bigley JE, Vaughn WK, Fraser CD Jr.

Ann Thorac Surg. 2002 Aug;74(2):355-62; discussion 362.

PMID:
12173813
19.

Effects of pulsatile and nonpulsatile perfusion on cerebral hemodynamics investigated with a new pediatric pump.

Undar A, Eichstaedt HC, Bigley JE, Deady BA, Porter AE, Vaughn WK, Fraser CD Jr.

J Thorac Cardiovasc Surg. 2002 Aug;124(2):413-6. No abstract available.

20.

Comparison of six pediatric cardiopulmonary bypass pumps during pulsatile and nonpulsatile perfusion.

Undar A, Eichstaedt HC, Masai T, Yang SQ, Bigley JE, McGarry MC, Mueller M, Vaughn WK, Fraser CD Jr.

J Thorac Cardiovasc Surg. 2001 Oct;122(4):827-9. No abstract available.

21.

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.

Peacock NW, Burris HA, Dieras V, Smith L, Rodriguez GI, Eckardt JR, Jones SF, Hardy J, Hohneker J, Bigley J, Von Hoff DD.

Invest New Drugs. 1998;16(1):37-43.

PMID:
9740542
22.

Electronic employee benefit management services.

Bigley JS.

Manag Care Interface. 1997 Oct;10(10):77-9.

PMID:
10174418
23.

Electronic enrollment: helping everyone make wise decisions.

Bigley JS.

Infocare. 1996 Nov-Dec:60-3. No abstract available.

PMID:
10162581
24.

Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.

Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J.

J Cancer Res Clin Oncol. 1996;122(9):554-8.

PMID:
8781570
25.

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J.

J Clin Oncol. 1995 Nov;13(11):2722-30.

PMID:
7595730
26.

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J.

J Clin Oncol. 1995 Oct;13(10):2567-74.

PMID:
7595708
27.
28.

Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.

Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, Jones SE, Bigley JW, Hohneker JA.

J Clin Oncol. 1995 Mar;13(3):637-44.

PMID:
7533824
29.

Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil.

Beitz JG, Damowski JW, Cummings FJ, Browne MJ, Clark JW, Bigley JW, Weitberg AB.

Cancer Invest. 1995;13(5):464-9.

PMID:
7552811
30.

Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.

Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Bigley J, Hohneker J.

Semin Oncol. 1994 Oct;21(5 Suppl 10):35-8; discussion 38-41.

PMID:
7973767
31.
32.

Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.

Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Arezzo J, Fischl MA, Powderly WG, Gocke DJ, Richman DD, Pottage JC, Antoniskis D, McKinley GF, Hyslop NE, Ray G, Simon G, Reed N, LoFaro ML, Uttamchandani RB, Gelb LD, Sperber SJ, Murphy RL, Leedom JM, Grieco MH, Zachary J, Hirsch MS, Spector SA, Bigley J, Soo W, Merigan TC.

Ann Intern Med. 1993 Mar 1;118(5):321-30.

PMID:
8094279
33.

High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial.

Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, et al.

Cancer. 1992 Dec 15;70(12):2929-34.

PMID:
1451076
34.

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, Metcalf JA, Bigley JW, Sawyer LA, Zoon KC, et al.

Ann Intern Med. 1989 Aug 15;111(4):280-7.

PMID:
2757312
35.

Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.

Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL.

N Engl J Med. 1988 Dec 15;319(24):1573-8.

PMID:
3059187
36.

Sustained-release theophylline therapy for chronic childhood asthma.

Bell T, Bigley J.

Pediatrics. 1978 Sep;62(3):352-8.

PMID:
704210
38.

Metastatic endocardial melanoma with anginal pain.

EVERTS-SUAREZ EA, BIGLEY J.

Pa Med J. 1962 Sep;65:1050-2. No abstract available.

PMID:
13891056

Supplemental Content

Loading ...
Support Center